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Abstract 
 Pre-diabetes is a serious health problem in the United States.  Distinguished by plasma 
glucose levels that are above the normal threshold, patients with pre-diabetes are 10 times more 
likely to develop type 2 diabetes.  Patients with pre-diabetes suffer the same complications as 
patients with diabetes including diabetic retinopathy, nephropathy, and microalbuminuria.   
There is considerable evidence to support the idea that early identification and aggressive 
treatment of pre-diabetes has the potential to delay disease progression.  The American Diabetes 
Association’s clinical practice guideline recommends management of with lifestyle modification 
and metformin for patients who are at risk for developing type 2 diabetes.  The purpose of this 
project was to evaluate the implementation of the 2012 ADA clinical practice guidelines 
regarding the management of patients with pre-diabetes by the health care providers at a 
volunteer-run clinic located in a large metropolitan area in the southeastern United States.   
 This study, even with a small sample size (n=26) revealed that the providers at the clinic 
had not implemented the 2012 ADA clinical practice guidelines.  Clinical practice guidelines 
promote health care interventions that have proven benefits and improve the consistency of care 
provided to patients.  The greatest benefits of implementing clinical practice guidelines for 
patients with pre-diabetes are early diagnosis and aggressive disease management.  This would 
improve patient outcomes and in the long run, decrease the cost of medical care. 
 
Keywords:  pre-diabetes, clinical practice guidelines, impaired fasting glucose, impaired glucose 
tolerance, metformin, pharmacologic intervention, prevention of type 2 diabetes 
 
 
 
 
 
 
Chapter One: Introduction  
Pre-diabetes is a precursor to diabetes and is a public health epidemic in the United States (Centers 
for Disease Control and Prevention [CDC], 2011).  Diabetes develops insidiously, during which time 
glucose metabolism progresses from normal to pre-diabetes, then to diabetes (Rhee et al., 2010).  Although 
most patients with pre-diabetes experience no symptoms, it, like diabetes, has the potential for significant 
morbidity and mortality.  This chapter provides an overview of pre-diabetes, discusses the extent and 
significance of the problem, and describes the current standards of care in pre-diabetes management.  It 
concludes with the clinical problem, purpose of project, and an operational definition of terms.  
Background 
Pre-diabetes is one of the most common medical conditions encountered in primary care (Fonseca, 
2007; O’Mara, 2008).  This chronic condition is distinguished by plasma glucose or glycosylated 
hemoglobin (HbA1C) levels that are above the normal threshold (American Diabetes Association [ADA], 
2012; Fonseca, 2007; O’Mara, 2008).  Pre-diabetes includes impaired fasting glucose (IFG), impaired 
glucose tolerance (IGT), and a combination of both IGT and IFG (ADA, 2012; Aroda & Ratner, 2008; 
CDC, 2011; Fonseca, 2007; World Health Organization [WHO], 2006).  The WHO and International 
Diabetes Federation defines IFG as a fasting plasma glucose (FPG) between 110 mg/dL and 126 mg/dL, 
and IGT as a FPG less than 126 mg/dL and blood glucose levels between 140 mg/dL and 200 mg/dL two 
hours after a 75 gram glucose drink (WHO, 2006).  The American Diabetes Association uses slightly lower 
criteria in the diagnosis of pre-diabetes (ADA, 2012).  Associated laboratory values for pre-diabetes 
include FPG levels between 100 mg/dL and 125 mg/dL, postprandial blood glucose levels between 140 
mg/dL and 199 mg/dL two hours after a 75 gram oral glucose load on a two hour oral glucose tolerance test 
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(2h OGTT), or a HbA1C range of 5.7 to 6.4% (ADA, 2012; Biuso, Butterworth, & Linden, 2007; Fonseca, 
2007; Pagana & Pagana, 2011).  Table 1 presents a comparison of the laboratory tests, values and 
associated pre-diabetic conditions according to the ADA and WHO.   
Table 1  
 
Comparison of Pre-Diabetes Laboratory Values by Health Organization 
 
Pre-Diabetic 
Condition 
Laboratory  
Test 
Diagnostic Laboratory Values` 
ADA WHO 
IFG FPG 100-125 mg/dL 110-125 mg/dL 
IGT FPG 
2h OGTT 
--- 
140-199 mg/dL 
<126 mg/dL 
>140 and <200 mg/dL 
Pre-Diabetes 
(IFG/IGT) 
HbA1c 5.7-6.4% Not recommended 
Note. Adapted from “Standards of Medical Care in Diabetes – 2012” by American Diabetes Association, 
2012, Diabetes Care, 35(Supplement 1), p. S16. Copyright 2012 by the American Diabetes Association. 
Adapted from “Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia” by World 
Health Organization, 2006, Geneva, Switzerland: World Health Organization, p. 3. Copyright 2006 by the 
World Health Organization. 
 
Prevalence of Pre-Diabetes and Diabetes 
The prevalence of diabetes continues to grow exponentially.  Diabetes was the seventh leading 
cause of death in the United States in 2007 and the risk of death among people with diabetes is nearly 
double that of people of similar age who do not have diabetes (CDC, 2011).  In 2011, approximately 79 
million, or 26%, of U.S. adults over 20 years of age had pre-diabetes (CDC, 2011; Cowie et al., 2009).  The 
latest data from the Centers’ for Disease Control (CDC) (2011) indicate that nearly 35% of non-Hispanic 
whites, 35% of non-Hispanic blacks, and 36% of Mexican Americans have pre-diabetes.   
Currently there are no data for the prevalence of pre-diabetes in the state of Florida or Duval 
County.  Data regarding diabetes, however, are suggestive that pre-diabetes is also a state and local 
problem as the prevalence of Floridians with diabetes increased by 57.4% from 1999 to 2009 (Florida 
Department of Health, Bureau of Epidemiology [Florida DOH], 2011).  According to self-reported 
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Behavioral Risk Factor Surveillance System (BRFSS) surveys, 10.7% of Florida adults have diabetes, 
which is approximately 1.5 million residents (Florida DOH, 2011).  The most recent data from the BRFSS 
indicate that 9.5% of non-Hispanic whites, 13.5% of non-Hispanic blacks, and 12.1% of Hispanics living in 
Florida have diabetes (Florida DOH, 2011).  
Diabetes and its complications are substantial causes of morbidity and mortality, reduced quality of 
life, and economic loss (CDC, 2011; Cowie et al., 2009).  The annual financial burden of diabetes in the 
U.S. exceeds $174 billion.  The average medical expenditure for patients with diabetes is 2.3 times higher 
than those without diabetes (CDC, 2011). 
Patients with pre-diabetes are 10 times more likely to develop type 2 diabetes (Rhee et al., 2010).  
These patients also suffer the same complications and comorbidities as patients with diabetes (ADA, 2012; 
Milman & Crandall, 2011; Rhee et al., 2010).  Evidence suggests even slight elevations in plasma glucose 
levels are associated with concomitant diabetic retinopathy, nephropathy, and microalbuminuria (Aroda & 
Ratner, 2008; Milman & Crandall, 2011, Ngatena & Kapustin, 2011; Parikh et al., 2010).  Other 
comorbidities associated with pre-diabetes include atherosclerosis, peripheral vascular disease, 
hyperlipidemia, cardiovascular disease, and stroke (ADA, 2012; Fonseca, 2007; Salyers, 2011; Scheen, 
2007; WHO, 2006).   
Standards of Care 
Early identification and aggressive treatment of persons with pre-diabetes has the potential to 
minimize disease progression and delay the onset of comorbidities associated with diabetes (ADA, 2012; 
CDC, 2012; Ngatena & Kapustin, 2011; Yuen, Sugeng, & Weiland, 2010).  The primary goal of clinical 
management of pre-diabetes is to help the body to use insulin properly while preventing or delaying the 
onset of overt type 2 diabetes.  “The Standards of Medical Care in Diabetes – 2012,” the ADA’s clinical 
practice guideline (CPG), recommends clinical management of pre-diabetes with lifestyle modification 
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(LSM) and metformin (ADA, 2012).  Pharmacotherapy with metformin is recommended as first line 
treatment for those at very-high-risk for developing type 2 diabetes.  This includes patients with a history 
of gestational diabetes (GDM), patients who are obese, and those with severe or progressive hyperglycemia 
(ADA, 2012).  Table 2 depicts the recommendations for the management of patients with metformin to 
prevent or delay progression to type 2 diabetes.  
Table 2 
Recommendations for the Management of Patients with Metformin 
 
Risk Factor or Medical Condition 
-Patients with IGT 
-Patients with IFG 
-Patients with a HbA1c of 5.7-6.4% 
-Body mass index (BMI) >35 kg/m
2 a 
-Age >60 years * 
-Women with prior diagnosis of gestational diabetes mellitus
a 
Note. Adapted from “Standards of Medical Care in Diabetes – 2012” by American Diabetes Association, 
2012, Diabetes Care, 35(Supplement 1), p. S16. Copyright 2012 by the American Diabetes Association. 
a 
Metformin should be considered especially if these patients have IGT, IFG, or HbA1c 5.7-6.4% 
 
Abbreviated Literature Review 
 Several studies and clinical reviews have examined the efficacy of various pharmacologic agents in 
preventing type 2 diabetes (Knowler et al., 2002; Lily & Godwin, 2009; Salpeter, 2008; Yuen et al., 2010).  
Metformin, however, is currently the only pharmacologic therapy recommended for the treatment of pre-
diabetes (ADA, 2012).  Evidence has found that metformin was as effective as LSM in preventing type 2 
diabetes in patients with a history of GDM and those patients with a BMI index of 35 kg/m2 or greater 
(ADA, 2012; Knowler et al., 2002). 
Problem 
 The health clinic utilized for this project provides free primary care and preventive medical services 
to the working uninsured in Jacksonville, Florida.  Chronic and acute conditions such as asthma, chronic 
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obstructive pulmonary disease, hypertension, hyperlipidemia, diabetes, coronary artery disease, upper 
respiratory infections, and pneumonia are managed through diagnosis, education, and medications.  The 
ADA’s clinical practice guidelines regarding the management of diabetes are updated and published in 
January of each year.  This provided an opportunity to evaluate the practices of health care providers at the 
clinic regarding the implementation of the 2012 ADA standards of care for the management of patients 
with pre-diabetes in the clinic.  The PICO statement for this project is: (P) Did health care practitioners 
providing primary care services at a clinic for the working uninsured (O) adhere to the (C) 2012 ADA 
clinical practice guidelines for the management of patients with pre-diabetes six months after (I) they were 
published?  
Project Purpose 
The purpose of this project was to evaluate the implementation of the 2012 ADA clinical practice 
guidelines regarding the management of patients with pre-diabetes by the health care providers at a clinic 
for the working uninsured.  Specifically this project evaluated if health care providers implemented the 
2012 ADA standards of care when managing patients with pre-diabetes using lifestyle modification, 
medication, or a combination of both. 
Project Description 
 The paradigm of evidence-based practice served as the framework for this project.  
Evidence-based practice is the diligent, precise, and thoughtful use of the best evidence when making 
decisions and providing care to patients (Melnyk & Fineout-Overholt, 2011).  This practice requires the 
health care practitioner to integrate clinical expertise with the best relevant, clinical evidence while 
considering the individual preferences of the patient (Melnyk & Fineout-Overholt, 2011; Sackeit, 
Rosenberg, Muir-Gray, Haynes, & Richardson, 1996).   
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This project utilized a retrospective analysis to evaluate provider practice regarding the management of 
patients with pre-diabetes starting six months after the publication of the guidelines.  The outcome measure 
was implementation of the 2012 ADA standards of care for patients with pre-diabetes. 
Definition of Terms 
Fasting Plasma Glucose (FPG)  
 A laboratory test that measures the amount of glucose in a person’s blood plasma after a period, 
usually eight hours, of fasting.  This test is used to screen for pre-diabetes and diabetes (Pagana & Pagana, 
2011). 
Gestational Diabetes (GDM)  
 High blood sugar or diabetes that starts or is first diagnosed during pregnancy.  This condition 
usually occurs approximately half way through the pregnancy.  Pregnant women are screened between the 
24
th
 and 28
th
 week of pregnancy for this condition (ADA, 2012).   
Hemoglobin A1c (HbA1c)  
 A laboratory test that measures the amount of glucose attached to hemoglobin.  It is used to 
diagnose and monitor pre-diabetes and diabetes treatment.  This test reflects the amount of glucose 
available in the blood stream over a red blood cell’s 120 day life span.  This test is also used to assess 
blood glucose control over a three to four month period (Pagana & Pagana, 2011). 
Impaired Fasting Glucose (IFG)  
 A pre-diabetic state in which the fasting blood glucose level is consistently elevated above the 
normal level, however, it is not high enough to be diagnosed as diabetes mellitus.  The ADA criterion 
defines IFG as having fasting glucose levels 100 mg/dL and 125 mg/dL (ADA, 2012). 
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Impaired Glucose Tolerance (IGT)   
 A pre-diabetic state of hyperglycemia where the glucose level is elevated after a two hour oral 
glucose load, however the glucose level does not meet criteria for type 2 diabetes mellitus.  A two-hour 
glucose level of 140 to 199 mg/dL on the 75-g oral glucose tolerance test is considered IGT (ADA, 2012).  
Lifestyle Modification (LSM)  
 Activities such as improved diet and nutrition, weight management, and exercise aimed at 
preventing diabetes and improving plasma glucose levels in patients with pre-diabetes (ADA, 2012).  
Metformin  
 The oral diabetic medication in the biguanide class that is approved for use in the United States.  It 
is the first-line drug of choice for the treatment of pre-diabetes.  Metformin works by suppressing glucose 
production and improving insulin action in the liver (Rizza & Vella, 2009).   
2 Hour Oral Glucose Tolerance Test (2h OGTT)  
 Referred to as the glucose tolerance test, this laboratory assay measures the body’s ability to 
metabolize glucose.  The test can be used to diagnose pre-diabetes, diabetes, or gestational diabetes 
(Pagana & Pagana, 2011).   
Pre-Diabetes  
 For the purposes of this study, the ADA (2012) criteria was used for the diagnosis of pre-diabetes 
(see Table 3).  
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Table 3  
ADA Diagnostic Criteria for Pre-Diabetes 
Diagnostic Test Laboratory Value 
FPG 100-125 mg/dL 
2h OGTT 140-199 mg/dL 
HbA1c 5.7-6.4% 
Note. Adapted from “Standards of Medical Care in Diabetes – 2012” by American Diabetes Association, 
2012, Diabetes Care, 35(Supplement 1), p. S16. Copyright 2012 by the American Diabetes Association. 
 
Type 2 Diabetes  
 A chronic disease in which there are elevated levels of glucose in the blood.  Type 2 diabetes is the 
most common form of diabetes (ADA, 2012).  
Working Uninsured Population  
 Persons who are employed and live in or work an average of 20 hours per week in Duval County or 
Jacksonville, Florida , and have an income of 1.5 times the poverty level or hold no health insurance.   
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Chapter Two: Review of Literature 
This chapter provides an overview of the literature sources and search strategies that were used to 
locate and retrieve the best evidence regarding the pharmacologic management of pre-diabetes with 
metformin.  This is followed by a discussion of the evidence regarding the use of HbA1c in the diagnosis 
and management of pre-diabetes.  Next the ADA clinical practice recommendations will be analyzed using 
the Appraisal of Guidelines for Research and Evaluation II (AGREE II) Instrument.  This chapter 
concludes with a synthesis and discussion of the evidence regarding the use of metformin and LSM in the 
treatment of pre-diabetes.  
Literature Sources and Search Strategies 
 For this review, the following databases were searched: UNF One Search, OVID, Medline, and 
Cochrane.  The following terms were used in various combinations to search the above databases: ADA 
clinical practice recommendations, impaired fasting glucose, impaired glucose tolerance, pre-diabetes, 
metformin, prevention of type 2 diabetes, pharmacological intervention, and HbA1c.  The initial search 
yielded 76,099 articles.  Searches were then limited to the years 2002 to 2012, the English language, meta-
analyses, and randomized controlled trials that were conducted with human subjects investigating the 
treatment of pre-diabetes with metformin or LSM.  A manual search of citations for duplicate articles, 
seminal studies, and relevant review articles was conducted.  The search was then updated through an 
examination of references from the RCT and meta-analyses. The final search yielded four recent meta-
analyses, one CPG, and one randomized controlled trial (RCT).   
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HbA1c in the Diagnosis and Management Pre-Diabetes 
In the past, pre-diabetes and diabetes were diagnosed exclusively using the FPG and OGTT.  The 
HbA1c, however, has emerged as a reliable and convenient tool in assessing plasma glucose levels.  The 
ADA now recommends using the HbA1c in the diagnosis and management of patients with pre-diabetes 
(ADA, 2012; Tankova, Chakarova, Dakovska, & Atanassova, 2011).  The use of HbA1c has some 
advantages over FPG and OGTT testing.  It does not require fasting or special scheduling.  The HbA1c also 
provides a clearer representation of chronic hyperglycemia and is more closely associated with the co-
morbidities associated with diabetes (Bonora & Tuomiletho, 2011; Buell, Kermah, & Davidson, 2007; 
Olson, Rhee, Herrick, & Ziemer, 2010; Tankova et al., 2011). 
The HbA1c assay is as precise, if not more accurate, in diagnosing and managing patients with pre-
diabetes than the FPG and the OGTT.  A study conducted by Silverman et al. (2011) confirmed the ADA 
standard of a HbA1c of 5.7% as the optimal cutoff for pre-diabetes.  This study found that a HbA1c of 
5.7% yielded a sensitivity of 54.8%, a specificity of 71.3%, a positive predictive value of 51.4, and a 
negative predictive value of 74.1 (Silverman et al., 2011).  A review of the 1999-2004 National Health and 
Nutrition Examination Survey (NHANES) data also found that a HbA1c of 5.8% has a sensitivity of 86% 
and a specificity of 92% for diagnosing pre-diabetes (Buell et al., 2007; Ngatena & Kapustin, 2011).  Once 
a patient has been diagnosed with pre-diabetes, HbA1c can be used to trend and monitor changes and 
improvements in glycemic control as it accurately reflects a patient’s average plasma glucose levels over a 
period of three to four months (ADA, 2012; Olson et al., 2010).   
Evaluation of the ADA Clinical Practice Recommendations 
Evidence-based CPGs are systematically developed assertions intended to assist clinicians in 
making informed making health care decisions (AGREE Next Steps Consortium, 2009; Brouwers, 
Makarski, & Levinson, 2010).  Clinical practice guidelines can also have a significant impact on health 
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care policy (Brouwers et al., 2010).  The “Standards of Medical Care in Diabetes-2012” is the ADA’s most 
recent CPG.  This document is reviewed and updated annually and also serves as the ADA’s all-inclusive 
position statement (ADA, 2012).   
The AGREE II Instrument was used to assess the global quality, methodological rigor, and 
transparency of the “Standards of Medical Care in Diabetes-2012.”  The purpose of this instrument is to 
provide a uniform approach and framework for assessing the quality of CPGs (AGREE Next Steps 
Consortium, 2009).  It is comprised of 23 criteria that assess CPGs according to six domains including 
scope and purpose, stakeholder involvement, rigor of development, clarity of presentation, applicability, 
and editorial independence (AGREE Next Steps Consortium, 2009; Brouwers et al., 2010).  A seven point 
likert scale, anchored with “1: strongly disagree” and “7: strongly agree,” was used to measure the extent to 
which each of the criteria are met by the CPG.   
The “Standards of Medical Care in Diabetes-2012” was evaluated by three board certified nurse 
practitioners that routinely encounter patients with pre-diabetes in their daily practice.  In general, the 
ADA’s CPG was considered a quality guideline receiving a 15 out of 21 (71%) on the overall assessment.  
The guideline received the highest score in Domain 1 with 60 out of 63 (95%), which appraises the 
reporting of the scope and purpose of the guidelines and the clarity of presentation of the guidelines and 
their lowest score in Domain 5 with 32 out of 84 (38%), which assesses the applicability of the guidelines.  
Although there is no recommended monitoring or benchmarking criteria presented in the CPG, it was 
found to be a quality guideline and is recommended for use.  Table 4 provides information regarding the 
overall assessment and domain scores for the “Standards of Medical Care in Diabetes – 2012” using the 
AGREE II Instrument. 
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Table 4  
Assessment of ADA Clinical Practice Guidelines Using AGREE II 
 
Domain/Area Evaluator 
1 
Evaluator 
2 
Evaluator 
3 
Total Score % Best Possible 
Score 
Domain 1: 
Scope and Purpose 
21 (100%) 20 (95%) 19 (90%)   60 (95%)    63 
Domain 2: 
Stakeholder 
Involvement 
18 (85%) 18 (85%) 19 (90%)   55 (87%)    63 
Domain 3: 
Rigor of Development 
48 (86%) 48 (86%) 51 (91%)   147 (88%)    168 
Domain 4: 
Clarity of Presentation 
20 (95%) 19 (90%) 19 (90%)   58 (92%)    63 
Domain 5: 
Applicability 
7 (25%) 12 (43%) 13 (46%)   32 (38%)    84 
Domain 6: 
Editorial Independence 
11 (79%) 11 (79%) 11 (79%)   33 (79%)    42 
Overall Assessment  
(Scale of 1-7) 
5 (71%) 5 (71%) 5 (71%)   15 (71%)    21 
Recommended for Use? Yes Yes Yes   Yes    Yes 
Note. Adapted from “The AGREE II Instrument” by AGREE Next Steps Consortium, 2009, retrieved from 
http://www.agreetrust.org. Copyright 2009 by the AGREE Research Trust. 
 
Analysis of Individual Studies 
The disease trajectory for pre-diabetes indicates that approximately one quarter of patients will 
progress to type 2 diabetes within three to five years and up to 83% of patients with pre-diabetes will 
develop overt diabetes (Nathan et al., 2007).  There is compelling evidence from several clinical trials and 
meta-analyses that this course can be changed.  Pharmacologic intervention with metformin combined with 
LSM can prevent or delay the progression to diabetes (ADA, 2012; Gillies et al., 2007; Knowler et al., 
2002; Lily & Godwin, 2009; Salpeter, 2008; Yuen et al., 2010).  The data supporting this relationship are 
outlined in Table 5 and Table 6.  
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Table 5 
Characteristics of Meta-Analyses and RCTs Investigating Metformin 
Author 
(Date) 
Design Sample Outcome Intervention Results Limitations 
Knowler et 
al. (2002) 
RCT 
 
Seminal 
study 
3,234 participants 
from 27 clinical 
centers around U.S. 
who were overweight 
and had pre-diabetes.  
Development 
of type 2 
diabetes 
Four groups:  
1. LSM 
2. Metformin 
twice a day 
3. Control 
4. Troglitazone 
LSM and treatment 
with metformin 
reduced the incidence 
of diabetes.  LSM 
was more effective 
than metformin. 
Did not take into 
account relative 
contribution of 
LSM in reduction 
of diabetes. 
Gillies et al. 
(2007) 
Meta-
analysis 
RCTs that evaluated 
interventions to delay 
type 2 diabetes in 
participants with 
IGT. 
Development 
of type 2 
diabetes 
No intervention, 
meta-analysis of 
17 RCTs 
LSM and 
pharmacological 
interventions slowed 
the progression to 
type 2 diabetes.  
Used Jadad 
scoring to rate 
RCTs however no 
explanation of 
tool. 
Salpeter 
(2008) 
Meta-
analysis 
RCTs that compared 
metformin with 
placebo or no 
treatment. 
Development 
of type 2 
diabetes  
No intervention, 
meta-analysis of 
31 RCTs 
Improvements in 
weight, lipid profiles, 
fasting glucose 
levels, and insulin 
resistance noted.  
Patients treated with 
metformin had a 40% 
decrease in the 
progression to 
diabetes 
No discussion of 
tool or instrument 
used to rate 
studies. 
Lily & 
Godwin 
(2009) 
Meta-
analysis 
RCTs involving 
administration of 
metformin to prevent 
diabetes in subjects 
with IFG/IGT.   
Development 
of type 2 
diabetes 
No intervention, 
meta-analysis of 
3 RCTs 
Metformin was 
effective in delaying 
the progression to 
diabetes. 
No use of 
electronic 
databases for 
search with 
overlap of some 
articles. 
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Author 
(Date) 
Design Sample Outcome Intervention Results Limitations 
Yuen, 
Sugeng, & 
Weiland 
(2010) 
 
Meta-
analysis 
RCTs that followed 
participants for one 
year.  Studies 
compared 
intervention with oral 
hypoglycemic and 
anti-obesity agents.  
Development 
of type 2 
diabetes 
No intervention, 
meta-analysis of 
4 RCTs 
Oral hypoglycemic 
and anti-obesity 
agents reduce the 
incidence of diabetes.   
Internal validity of 
instrument used to 
assess studies for 
inclusion. 
Note. Adapted from Evidence Based-Practice in Nursing and Healthcare (2nd ed.) (p. 515-516) by B. M. Melnyk and E. Fineout-
Overholt, 2011, Philadelphia, PA: Lippincott Williams & Wilkins. Copyright 2011 by Wolters Kluwer Health Lippincott Williams 
&Wilkins. 
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Table 6 
Characteristics of Clinical Trials Evaluating the LSM and Medication 
 
Trial/Year Location Population Age/Gender Intervention
a 
Conclusion Criteria 
Pan, 1997 China n=530 with IGT >25 years 
283 men/247 women 
LSM LSM decreases the 
incidence of diabetes 
among those with 
IGT. 
WHO 
1985 
Finnish 
Diabetes 
Prevention 
Study, 1993 
Finland n=522 with IGT AGE 
33% men/67% women 
LSM LSM reduced diabetes 
risk.  
WHO 
1985 
Japanese 
Diabetes 
Prevention, 
2005 
Japan n=240 with IGT Mean Age=51 
51% men/49% women 
LSM LSM is useful in 
preventing diabetes in 
Japanese with IGT.  
WHO 
1999 
Kosaka, 2005 Japan n=356 with IGT Age 30-70 
100% men 
LSM LSM aimed at 
achieving ideal body 
weight in men with 
IGT is effective. 
WHO 
1980 
Liao, 2002 U.S. n=70 with IGT 
 
Mean Age 55.8 
45% men/55% women 
LSM LSM may prevent 
diabetes in Japanese 
Americans with IGT 
WHO 
1998 
Wein, 1999 Australia n=200 with 
history of GDM 
and IGT 
Age 38-40 
100% women 
LSM Incidence rates of 
diabetes mellitus were 
lower with metformin 
than control group.   
WHO 
1985 
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Trial/Year Location Population Age/Gender Intervention
a 
Conclusion Criteria 
EDIT, 2003 UK n=631, some 
with IGT 
Age 30-70 
49% men/51% women 
 
M  Risk of diabetes not 
reduced with 
metformin or 
combination therapy.  
The ability of 
therapies to reduce 
risk of diabetes may 
differ for those with 
IGT or IFG. 
WHO 
1985 
Li, 1999 China n=90 with IGT  Age 30-60  M Metformin reduces the 
rate of type 2 diabetes. 
WHO 
1985 
Diabetes 
Prevention 
Program, 2002 
U.S. n=3234 with 
IGT 
 
Age > 25 
33% men/68% women 
B LSM and treatment 
with metformin 
reduced the incidence 
of diabetes.  
ADA 
1997 
Indian 
Diabetes 
Prevention 
Program, 2006 
India n=531 with IGT 
 
Age 35-55 
79% men/21% women 
B LSM and metformin 
reduced the incidence 
of diabetes in Asian 
Indians with IGT; 
there was no added 
benefit from 
combining them. 
WHO 
1999 
Note. Adapted from “Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose 
tolerance” by Gillies et al., 2007, British Medical Journal, 334, pp. 2-3.  Copyright 2012 by BMJ Publishing Group Limited. 
a 
Intervention abbreviations – LSM=lifestyle modification, M=metformin, B=LSM and metformin 
.
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Randomized Control Trial: Seminal Study 
The Diabetes Prevention Program Research Group (DPP) conducted a seminal study 
regarding the management of patients with pre-diabetes in the United States.  This landmark, 
multicenter RCT evaluated the effect of pharmacotherapy with metformin and LSM on the 
development of type 2 diabetes in 3,234 obese participants with pre-diabetes (Knowler et al., 
2002).  In the DPP, participants from 27 clinical sites in the United States were randomly 
assigned to one of four different interventions: LSM, metformin, troglitazone, and placebo or 
control.  The troglitazone portion of the study was discontinued prior to the completion of the 
study, because troglitazone was discovered to cause liver damage. 
The goal for participants assigned to the LSM segment of the DPP was moderate weight 
loss through improved nutrition and increased physical activity.  Participants in LSM group 
partook in a 16-week curriculum covering exercise, nutrition, and behavior modification 
strategies while participants assigned to the metformin group received 850 mg of metformin 
twice daily.  The LSM group experienced a 58% (95% Confidence Interval [CI], 48-66) 
reduction in the risk of developing diabetes and the metformin group experienced a 31% (95% 
CI, 17-43) reduction in the risk of developing diabetes (Knowler et al., 2002).   Metformin was 
maximally effective in participants from ages 25 to 44 years and those who were at least 60 
pounds overweight (Knowler et al., 2002).   
The results of the DPP are significant and imply that LSM and pharmacotherapy with 
metformin are useful in the prevention of diabetes.  Participants in both the LSM and metformin 
groups experienced lower rates of progression to overt diabetes as compared to 11% for those 
participants assigned to the placebo or control group.  These findings were true for both genders 
and across all ethnic groups included in the study (Knowler et al., 2002).   
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Meta-Analyses 
 Gillies et al. (2007) performed a meta-analysis of RCTs that examined the efficacy of 
lifestyle and pharmacologic interventions designed to delay or prevent type 2 diabetes in patients 
with IGT.  A total of 17 trials from 1979 to 1996 with 8,084 participants were included.  Based 
on the time period covered in the meta-analysis, multiple diagnostic criteria for type 2 diabetes 
and IGT were used.  Most diagnostic criteria for type 2 diabetes however, were analogous, as 
they required a plasma glucose level of ≥11.1 mmol/l on the 2 h OGTT and a FPG concentration 
of ≥7.8 mmol/l.  The criterion used to define IGT was 7.8-11.1 mmol/l on the 2 h OGTT.   
Gillies et al. (2007) performed four meta-analyses on studies targeting LSM and 
pharmacologic interventions.  Each meta-analysis yielded evidence that LSM and pharmacologic 
intervention can successfully prevent or delay the onset of type 2 diabetes.  A comprehensive 
meta-analysis of LSM employed revealed a pooled hazard ratio of 0.51 (95% CI, 0.44-0.60, 
p<0.001) indicating a 49% relative reduction in the development of diabetes.  The pooled hazard 
ratio for anti-diabetic medications was 0.44 (0.28-0.69, p<0.001) for anti-diabetic medication 
indicating a 56% reduction in the relative risk of developing diabetes. 
The RCTs included in the meta-analysis by Gillies et al. (2007) were heterogeneous in 
terms of interventions applied, ethnicity, weight, and age.  The meta-analysis of LSM identified 
no reporting or publication bias (Begg’s test p=0.945 and Egger’s test p=0.340).  Reporting 
biases however, may have limited the assessment of the efficacy of anti-diabetic medications in 
reducing or delaying the onset of type 2 diabetes (Begg’s test p=0.012 and Egger’s test p=0.058).   
 A similar meta-analysis by Yuen et al. (2010) included a total of four RCTs.  The number 
of subjects in the included studies ranged from 178 to 3,234.  The primary outcome measure for 
each RCT was the diagnosis of type 2 diabetes according to the 2h OGTT.  The criteria used to 
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define type 2 diabetes however, varied from study to each study.  The ADA criterion for type 2 
diabetes was used in one study, and the WHO criteria were used in three.  The overall risk of 
bias in the four studies was high.  Based on the evidence presented in each study, the authors did 
not speculate as to which intervention was more effective in preventing type 2 diabetes.  The 
authors however, concluded that LSM and pharmacologic intervention with metformin slow the 
onset of type 2 diabetes in patients with pre-diabetes.  
 Lily and Godwin (2009) conducted a meta-analysis of RCTs that evaluated the efficacy 
of metformin in preventing the onset of type 2 diabetes in patients with IFG or IGT.  Incident 
diabetes was a required outcome measure; follow-up time of a minimum of six months was also 
required.  A total of three RCTs from 1999 to 2002 with 42,932 participants from India, China, 
and the United States were included.  The metformin dosage administered and the rate of 
progression to diabetes varied across the RCTs.  This meta-analysis revealed that regardless of 
gender or ethnicity, study participants who were treated with metformin experienced a lower rate 
of conversion from pre-diabetes to diabetes (Odds Ratio [OR] 0.65, 95% CI, 0.55-0.78, 
p<.00001).  These findings support the hypothesis that pharmacotherapy with metformin delays 
the onset of type 2 diabetes in patients with pre-diabetes.   
 A recent meta-analysis by Salpeter (2008) showed that metformin is beneficial in the 
treatment of pre-diabetes.  This study included 31 RCTs with 4,570 patients who were monitored 
for 8,267 patient years.  The trials included in this meta-analysis assessed pre-diabetic patients 
from various populations and ethnic backgrounds.  Metformin was shown to significantly 
decrease weight, improve insulin resistance, and reduce the incidence of type 2 diabetes by 40% 
with a pooled OR of 0.6 (95% CI, 0.5-0.8).   
 20 
Summary 
 In summary, the evidence from the clinical trials and meta-analyses demonstrates that 
pharmacologic intervention with metformin combined with LSM can prevent or delay the 
progression to diabetes.  Many of the clinical trials included in these meta-analyses serve as the 
basis of the 2012 ADA standards for patients with pre-diabetes.  Due to the insidious nature of 
pre-diabetes, aggressive management with LSM and medication are now cornerstones of care.  
These are the standards by which the clinical management of pre-diabetes was evaluated at the 
clinic for the working uninsured. 
 21 
 
 
Chapter Three: Methodology 
This chapter includes a description of the design, sample, and data collection tool used 
for this quality improvement project.  There is also a discussion of the methods and procedures 
for the project including the protection of human subjects.  The purpose of this project was to 
evaluate the implementation of the 2012 ADA clinical practice guidelines regarding the 
management of patients with pre-diabetes by the health care practitioners at a clinic for the 
working uninsured. 
Study Design 
This study utilized a retrospective review with a one-group post only design.  Data was 
collected from patient charts for the three month period between July and September 2012.  This 
time period was chosen because it was six months after the 2012 ADA clinical practice 
guidelines were published. 
Setting 
The setting for this study was a volunteer-run clinic located in a large metropolitan area 
in the southeastern United States.  This clinic includes both physicians and nurse practitioners 
who provide primary care services to uninsured, working adults and their families.   
Sample 
A retrospective analysis of 50 medical records were reviewed sequentially to evaluate the 
implementation of the 2012 ADA clinical practice guidelines regarding the management of 
patients with pre-diabetes by the health care practitioners at the clinic for the working uninsured.  
Permission to conduct this quality improvement project was obtained from the investigator’s 
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project committee, the Institutional Review Board (IRB) at the University of North Florida, and 
the executive board of the clinic (Appendix B and Appendix C). 
Methods 
Data was collected for the timeframe covering July to September 2012, which was six 
months after the 2012 ADA clinical practice guidelines were published.  Charts for this study 
were identified by the clinic staff including individual providers, the chief information officer, 
and the clinical and medical directors.  Potential charts for this study were also identified using a 
search according to diagnosis and International Classification of Disease Ninth Edition Clinical 
Modification (ICD-9-CM) codes.  Diagnoses that were searched included pre-diabetes, IFG, and 
IGT.  Searches according to ICD-9-CM included 790.21, 790.22, and 790.29. 
Data Collection 
Data was collected for the timeframe covering July to September 2012.  All data was 
collected by the principal investigator and was de-identified and documented on the study data 
collection sheet.  The data collection sheet that was used in the study is located in Appendix D.  
After potential charts were identified, the following steps were taken during this project to 
collect the data: 
1. All charts remained at the clinic. 
2. Each chart was assigned a unique study “n” number different from the patient 
identification number used in the clinic.  The purpose of the “n” study number 
was to assist the principal investigator in tracking the total number of charts that 
were reviewed during the study. 
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3. Each chart was verified to ensure that the patient was over the age of 18.  If there 
was evidence in the chart that the patient was under the age of 18, the chart was 
excluded from the study. 
4. Each chart was reviewed to verify a diagnosis of pre-diabetes according to the 
2012 ADA criteria.  If there is no was no evidence of a diagnosis of pre-diabetes 
according to the ADA 2012 criteria in the patient chart, it was excluded from the 
study (see data collection tool, Appendix D). 
5. Each chart was reviewed to verify that care for pre-diabetes was provided during 
the timeframe from July to September 2012.  If there was no evidence that care 
for pre-diabetes was provided during that timeframe, it was excluded from the 
study (see data collection tool, Appendix D). 
6. All data was de-identified. 
7. Demographic data included the time period or month in which care was provided 
(see data collection tool, Appendix D). 
8. Data collected included treatment modalities employed for the management of 
pre-diabetes.  These treatment modalities included no treatment, LSM, 
medication, or a combination of LSM and medication (see data collection tool, 
Appendix D). 
Fesaibility 
 This project was designed to evaluate the implementation of the 2012 ADA clinical 
practice guidelines regarding the management of patients with pre-diabetes by the health care 
providers at a clinic for the working uninsured.  The staff at the clinic is dedicated to providing 
evidence-based primary care and specialty services to the community’s working uninsured.  The 
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clinic staff is continuously looking toward quality improvement and are willing to update and 
change their practices to benefit patients.  The data and results obtained from this quality 
improvement project are not generalizable.  The outcomes however, will provide valuable 
information to the clinic staff regarding the implementation of the 2012 ADA standards of care 
by the providers.   
Income and Expenses 
 The primary expenses for this project included office supplies and printing.  These 
expenses were considered negligible and were incurred by the principal investigator.  
Protection of Human Subjects 
This study evaluated existing data from patient charts.  Minimal risk was associated with 
this project.  A waiver of consent and a waiver of the Health Insurance Portability and 
Accountability Act of 1996 (HIPAA) regulations was requested and granted by the IRB at the 
University of North Florida.  Risk of breach of confidentiality however, is an associated risk with 
any chart review.  To mitigate this risk and to ensure that the privacy and security of the data 
obtained during the study, all HIPAA regulations were followed.  All patient records remained at 
the clinic.  Additionally, no individually identifying data was collected.  Data from this project 
was collected and recorded on the data collection sheet and transferred to an electronic 
spreadsheet (Appendix D).   
Confidentiality 
Data was stored in a locked file cabinet in the home office of the principal investigator.  
The data was de-identified and not linked to any identifiable information from the medical 
record, and used only in aggregate.  Each record was assigned a unique study number which was 
recorded on the data collection sheet.   
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Data was entered into an electronic spreadsheet on the principal investigator’s laptop 
computer, which was protected by a password.  Data from the spreadsheet was uploaded into a 
Statistical Package for the Social Sciences (SPSS) database.  Once data collection was complete, 
all data was entered, verified and analyzed, all project-related documents were destroyed. 
Data Analysis Plan 
All raw data entered was entered into the computer and checked for errors.  Data was 
analyzed using SPSS (version 21.0, 2012, Armonk, NY) with statistical significance determined 
at p≤0.05.  Descriptive statistics such as frequency, percentage, mean, and significance level 
were used to analyze the implementation of the 2012 ADA standards of care for patients with 
pre-diabetes at the clinic.  Trends in the implementation of the 2012 ADA standards of care were 
considered significant. 
Summary 
 This chapter describes the methodology for this project, the permissions that were 
obtained in order to conduct this quality improvement project, and the data analysis plan.  Data 
for this projected were collected using the timeframe covering July to September 2012.  Data 
collected during this project were used to evaluate provider practices regarding the management 
of pre-diabetes according to the 2012 ADA standards of care.  Data analysis provided valuable 
information for the clinic providers regarding evidence-based practice when caring for patients 
with pre-diabetes. 
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Chapter Four: Results 
This chapter provides a description of the sample and the disposition of the medical 
records that met inclusion criteria.  Sample characteristics including the time period in which 
pre-diabetes care was received, treatment modality provided, and if the pre-diabetes care that 
was provided met the 2012 ADA standards of care, were described using descriptive statistics 
including the frequency and percentage of the variables.  Analyses were executed using SPSS 
statistical software (version 21.0, 2012, Armonk, NY) with statistical significance determined at 
p ≤ .05.   
Sample Characteristics 
 Fifty medical records were initially identified for inclusion in the study.  Medical records 
of 26 patients met the inclusion criteria and were included in the final analysis.  All charts 
included in the study were of patients over the age of 18 who met the ADA criteria for a 
diagnosis of pre-diabetes and had care for pre-diabetes documented during the period from July-
September 2012.  A total of 24 charts were excluded: five charts were unavailable because the 
patients were no longer enrolled in the clinic; four charts did not meet the ADA diagnostic 
criteria for pre-diabetes; and, 15 charts did not have care documented during the time period of 
interest.  Figure 1 depicts the disposition of the charts identified for inclusion in the study (see 
Figure 1). 
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Figure 1. Chart disposition.  This figure illustrates the disposition of the charts identified for 
inclusion in the study. 
 
Time Period of Pre-Diabetes Care 
The medical records reviewed had pre-diabetes care documented in each of the three time 
periods representing July 2012, August 2012, and September 2012 with equal probability, 
2
(25, 
n=26) = 0.34, p=.05.  During the period covering July 2012, 12 (46.2%) records had care 
documented for pre-diabetes.  Eight charts (30.8%) had care for pre-diabetes documented during 
the period covering August 2012, and six charts (23.1%) had pre-diabetes care documented 
during the period covering September 2012.  Table 7 depicts the time period in which pre-
diabetes care was provided during the study. 
 
Table 7 
 
Time Period of Pre-Diabetes Care  
 
   Month Frequency Percent 
 
July 12 46.2 
August 8 30.8 
September 6 23.1 
Total 26 100.0 
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Treatment Modality 
Eight (30.8%) of the medical records reviewed during the study had no documentation of 
treatment for pre-diabetes.  A total of 18 of the medical records reviewed (69.2%) had 
documentation of some type of treatment for pre-diabetes documented during the study period.  
One (3.8%) medical record had evidence of a combined approach using LSM and metformin to 
manage pre-diabetes, while 17 (65.4%) medical records had evidence of LSM as the primary 
treatment modality for pre-diabetes. 
The categories of LSM documented in the medical records that were reviewed included 
singular modifications such as nutrition counseling (n=6, 35.3%), increased activity or exercise 
(n=1, 5.9%), weight loss (n=1, 5.9%) as well as combined adjustments including nutrition 
counseling and increased activity or exercise (n=1, 5.9%), and nutrition counseling and weight 
loss (n=8, 47.1%) (see Table 8).  The type of LSM documented in the reviewed records occurred 
with different probabilities, 
2
(16, n=17) = 0.010, p=.05. 
Table 8 
 
Type of LSM Documented in Records Reviewed 
 
Type of LSM  Frequency Percent 
8 
Nutrition 6 35.3 
Weight 1 5.9 
Exercise 1 5.9 
Nutrition + Weight 8 47.1 
Nutrition +Exercise 1 5.9 
Total 17 100.0 
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Standards of Care 
Of the medical records reviewed for the study, 25 (96.2%) had no evidence that the 2012 
ADA standards of care for patients with pre-diabetes was provided.  This included eight (30.8%) 
records that had no documented treatment for pre-diabetes and 17 (65.4%) records that had 
evidence of only LSM for the treatment of pre-diabetes.  One (3.8%) medical record met the 
standard of care with documentation of a combined approach using LSM and metformin for the 
treatment of pre-diabetes (See Figure 2).   
 
Figure 2. Charts with evidence that standard of care was met. This bar graph compares the 
number of records that met the standard of care with the number record that did not meet the 
standard of care.   
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Summary 
This chapter provided a description and discussion of the characteristics of the medical 
records that were reviewed during this study.  It describes the study outcomes according to the 
time period that pre-diabetes care was provided and the treatment modality prescribed.  A 
comparison of the prescribed treatment modality documented in the medical records according to 
the 2012 ADA standards of care is also made in this chapter.   
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Chapter Five: Discussion 
This chapter provides a discussion of the project outcomes relevant to the practitioners’ 
use of clinical practice guidelines for patients with pre-diabetes.  This discussion is followed by 
the limitations of the study.  Implications for evidence-based practice and recommendations for 
future projects are also presented. 
Discussion 
Pre-diabetes is one of the most common conditions encountered in primary care.  Nearly 
one quarter of adult patients over the age of 20 have pre-diabetes (CDC, 2011; Cowie et al., 
2009).  There is compelling evidence that early identification and aggressive treatment of 
persons with pre-diabetes with metformin and LSM can slow or prevent disease progression 
(ADA, 2012; Gillies et al., 2007; Knowler et al., 2002; Lily & Godwin, 2009; Salpeter, 2008; 
Yuen et al., 2010). 
The purpose of this project was to evaluate the implementation of the 2012 ADA clinical 
practice guidelines regarding the management of patients with pre-diabetes by the health care 
providers at a clinic for the medically uninsured.  Specifically, this project evaluated if the health 
care providers at the clinic implemented the 2012 ADA standards of care when managing 
patients with pre-diabetes using LSM, medication, or a combination of both.  The desired 
outcome was that the health care providers treated patients with pre-diabetes according to the 
2012 ADA standards of care and used a combined approach of LSM and medication.  Although 
majority of records reviewed in this study had documentation of LSM as the primary treatment 
modality for pre-diabetes, only one medical record reviewed during this study met the 2012 
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ADA standards of care.  These results suggest that in the charts reviewed for this study that the 
providers at the clinic were not following the 2012 ADA standards of care. 
 When examining the time periods when pre-diabetes care was provided, it was expected 
that during each successive month a greater percentage of charts would meet the 2012 ADA 
standards of care.  The medical records reviewed in this study were evenly distributed across the 
three time periods of care.  The only medical record that met the 2012 ADA standards of care, 
however, had pre-diabetes care documented during July 2012, the first period of care.   
Limitations 
 There were many limitations to this project that should be noted.  These include sample 
size, study design, and study setting.  The project design was chosen because it was a good fit 
based on the time constraints and setting where this quality improvement project was conducted. 
This study utilized a retrospective review with a one-group post only design.  A one-
group post-only design does not provide baseline information for comparison, nor does it 
account for extraneous influences that may have an effect on the dependent variable.  A one-
group pretest-posttest design is a more suitable option in future studies.  This design provides 
baseline information that measures the effect by examining the difference between the pretest 
and posttest scores.  
Another limitation to the study was the small sample size.  The final sample included a 
convenience sample of 26 medical records.  For this reason, the findings from this study cannot 
be generalized to the broader community.  The small sample size and the demographic 
information collected also precluded any complex statistical evaluation.  Future quality 
improvement projects utilizing medical records reviews to evaluate clinical practice should 
perform an ongoing review with a larger, more robust sample.  With an expected attrition of 
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approximately 50% of the medical records, there would be a more realistic approximation of a 
normal distribution. 
This study was conducted at only one institution in a large metropolitan area in the 
southeastern United States.  The clinic has a unique provider base and serves a specialized 
population.  Most of the primary care providers at the clinic are volunteers and many of the 
providers are retired.  The clinic serves working uninsured patients and their families.  This study 
requires replication in settings with paid providers as well as in settings with insured patients. 
Implications for Practice 
The results of this project highlight some of the complex issues associated with 
implementing evidence-based practice changes.  Evidence-based practice requires healthcare 
providers to synthesize and apply credible evidence to individual patient situations while using 
their clinical judgment and considering the patient’s values and resources (Melnyk & Fineout-
Overholt, 2011).  Implementing evidence-based clinical practice guidelines also requires a 
concerted effort from the leadership and individual providers.  Although some providers may 
follow evidence-based guidelines, a large majority of providers do not subscribe to them.  
It is recommended that the clinic identify a clinical area such as pre-diabetes to promote 
best practice and the implementation of the 2012 ADA clinical practice guidelines.  Adoption of 
the 2012 ADA clinical practice guidelines has the potential to improve patient outcomes.  
Treating patients according to the 2012 ADA standards of care will also ensure that the providers 
at the clinic are delivering standardized, high-quality care in a cost-effective manner.   
Recommendations 
The strategic plan at the clinic includes improving the health of the community through 
education and preventative medicine.  The adoption of the 2012 ADA clinical practice guidelines 
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for patients with pre-diabetes fits into this strategic plan.  The leadership, the providers, and the 
support staff at the clinic need to be involved in future projects.   
With a few modifications, this project could easily be reproduced in the clinic.  An 
educational program regarding pre-diabetes could be created for patients and providers.  This 
program would provide disease specific information and would focus on the importance of 
treating pre-diabetes according to the 2012 ADA clinical practice guidelines.  Early 
identification and aggressive treatment of pre-diabetes has the potential to delay disease 
progression and the development of type 2 diabetes.   
Conclusion 
Pre-diabetes remains a serious health problem in the United States.  The presence of pre-
diabetes significantly increases the risk of type 2 diabetes.  Management of patients with pre-
diabetes according to the 2012 ADA standards of care has the potential to delay the onset of type 
2 diabetes and its associated comorbidities.  The challenge is motivating health care providers to 
implement evidence-based practice changes and use clinical practice guidelines.   
Even with a small sample size, this study revealed that the providers did not use the 2012 
ADA clinical practice guidelines.  Clinical practice guidelines such as the 2012 ADA standards 
of care promote health care interventions that have proven benefits.  Clinical practice guidelines 
improve the consistency of care provided to patients.  The greatest benefits of implementing 
clinical practice guidelines for patients with pre-diabetes include early diagnosis and aggressive 
disease management.  This would improve patient outcomes and, in the long run, decrease the 
cost of medical care. 
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Appendix A: Critical Analysis Table: Review of Meta-analyses 
 
Question  Lily & Godwin. 
(2009) 
Salpeter. 
(2008) 
Yuen, Sugeng, & 
Weiland. (2010)  
Will the answer if true, have a direct bearing on the health of patients?  Yes Yes Yes 
Is the outcome or topic something that patients/clients/population groups 
would care about?  
Yes Yes Yes 
Is the problem addressed in the review one that is relevant to practice?  Yes Yes Yes 
Will the information, if true, require a change in practice?  Yes Yes Yes 
Was the question for the review clearly focused and appropriate?  Yes Yes Yes 
Was the search strategy used to locate relevant studies comprehensive? 
Were the databases searched and the search terms used described?  
Yes Yes Yes 
Were explicit methods used to select studies for the review? Were 
inclusion/exclusion criteria specified? Were selection methods unbiased?  
Yes Yes Yes 
Was there an appraisal of the quality/validity of studies included in the 
review? Were appraisal methods specified, appropriate, and reproducible?  
Yes Yes Yes 
Were specific treatments/interventions/exposures described? Were 
treatments similar enough to be combined?  
Yes Yes Yes 
Was the outcome of interest clearly indicated? Were other potential harms 
and benefits considered?  
Yes Yes Yes 
Were processes for data abstraction, synthesis, and analysis described? 
Were they applied consistently? Was there appropriate use of qualitative 
and/or quantitative synthesis? Was variation in findings among studies 
analyzed? Was heterogeneity considered? If data from studies were 
aggregated for meta-analysis, was the procedure described?  
Yes Yes Yes 
Are the results clearly presented in narrative? If summary statistics are used, 
are levels of significance and/or confidence intervals included?  
Yes Yes Yes 
Are conclusions supported by results with biases and limitations taken into 
consideration? Are limitations of the review identified and discussed?  
Yes Yes Yes 
Was bias due to the review’s funding or sponsorship unlikely?  No No No 
Note. Adapted from Evidence Based-Practice in Nursing and Healthcare (2nd ed.) (p. 515-516) by B. M. Melnyk and E. Fineout-
Overholt, 2011, Philadelphia, PA: Lippincott Williams & Wilkins.  Copyright 2011 by Wolters Kluwer Health Lippincott Williams 
&Wilkins. 
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Appendix D: Data Collection Sheet 
 
Data Collection Sheet:  Practitioners’ Use of Clinical 
Practice Guidelines in Patients with Pre-diabetes 
 
Study n #          
 
Chart of patient over the age of 18?    □ Yes  □ No* 
 
Care provided during July-September 2012 timeframe? □ Yes  □ No* 
 
Meets ADA 2012 definition of pre-diabetes?   □ Yes  □ No* 
 
 Criteria used to diagnose pre-diabetes, check one: 
 
 □ FPG level  □ HbA1c level □ 2h OGTT level 
 
Demographic Information 
Time period when care was provided □ Period 1    □ Period 2    □ Period 3 
 
Comparable Data 
Evidence of treatment for pre-diabetes □ Yes  □ No 
Lifestyle Modification □ Yes  □ No 
Type of Lifestyle Modification 
□ Nutrition   □ Exercise 
□ Weight Management □ Other______________ 
Medication □ Yes  □ No 
 
* - Initial inclusion criteria not met, stop chart review 
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